Free Trial
NASDAQ:PRTG

Portage Biotech Q3 2024 Earnings Report

Portage Biotech logo
$5.38 +0.09 (+1.70%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$6.59 +1.21 (+22.45%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Portage Biotech EPS Results

Actual EPS
-$3.60
Consensus EPS
-$5.40
Beat/Miss
Beat by +$1.80
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Portage Biotech Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Wednesday, February 28, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Portage Biotech's Q3 2025 earnings is scheduled for Thursday, June 26, 2025, with a conference call scheduled on Tuesday, July 1, 2025 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Portage Biotech Earnings Headlines

Portage Biotech Regains Nasdaq Compliance
When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Portage Biotech Inc. (PRTG) Cash Flow - Yahoo Finance
See More Portage Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:PRTG), a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

View Portage Biotech Profile

More Earnings Resources from MarketBeat